A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus
(Q42983656)
scientific article published on 27 February 2004
scientific article published on 27 February 2004
Language:
| (P31) |
(Q13442814)
|
||||||||||||||||
| (P304) |
964-970
|
||||||||||||||||
| (P407) |
(Q1860)
|
||||||||||||||||
| (P433) |
6
|
||||||||||||||||
| (P478) |
189
|
||||||||||||||||
| (P577) |
Friday, February 27, 2004
|
||||||||||||||||
| (P921) |
(Q421862)
(Q708693)
(Q154869)
(Q7160835)
|
||||||||||||||||
| (P1433) |
(Q4051141)
|
||||||||||||||||
| (P1476) |
"A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus" (language: en)
|
||||||||||||||||
| (P2093) |
G L Drusano
S L Preston
|